Effects of sibutramine on body weight and serum lipids: A double-blind, randomized, placebocontrolled study in 322 overweight and obese patients with dyslipidemia

American Heart Journal

Volumn 142, Issue 3, 2001, Pages 489-497

  Dujovne, Carlos A ^a,b,c   Zavoral, James H ^a,b,c   Rowe, Everton ^a,b,c   Mendel, Carl M ^a,b,c  

^a Kansas Foundation for Clinical Pharmacology   (United States)

^b FAIRVIEW SOUTHDALE HOSPITAL   (United States)

^c ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; PLACEBO; SIBUTRAMINE; TRIACYLGLYCEROL;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; DYSLIPIDEMIA; FEMALE; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION;

EID: 0034878265     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2001.117510     Document Type: Article

References (46)

1. Obesity as an independent risk factor for cardiovascular disease: A 26-year follow-up of participants in the Framingham Heart Study
2. Obesity and coronary heart disease
3. Effect of weight on cardiovascular disease
4. Excess body weight: An under-recognized contributor to high blood cholesterol levels in white American men
5. Excess body weight: An under-recognized contributor to dyslipidemia in white American women
6. Plasma triglyceride as a risk factor for cardiovascular disease
7. Triglyceride concentration and ischemic heart disease: An eight-year follow-up in the Copenhagen Male Study
8. Atherosclerosis prevention for the next decade: Risk assessment beyond low density lipoprotein cholesterol
9. Effect of weight loss on serum lipoprotein(a) concentrations in an obese population
10. Effects of weight reduction on blood lipids and lipoproteins: A meta-analysis
11. Relation of weight loss to changes in serum lipids and lipoproteins in obese women
12. A review of long-term studies evaluating the efficacy of weight loss in ameliorating disorders associated with obesity
13. Clinical pharmacologic concepts for the rational selection and use of drugs for the management of dyslipidemia
14. Cholesterol reduction
15. Weight loss attempts in adults: Goals, duration, and rate of weight loss
16. Current views on obesity
17. Long-term weight control study: Conclusions
18. Long-term pharmacotherapy in the management of obesity
19. Pharmacological approaches to intervention
20. Use and abuse of appetite-suppressant drugs in the treatment of obesity
21. Effect on radiolabelled-monoamine uptake in vitro of plasma taken from healthy volunteers administered the antidepressant sibutramine HCl
22. In vivo criteria to differentiate monoamine reuptake inhibitors from releasing agents: Sibutramine is a reuptake inhibitor
23. Investigation of the mechanisms underlying the hypophogic effects of the 5-HT and noradrenaline reuptake inhibitor, sibutramine, in the rat
24. Sibutramine reduces food intake in non-dieting women with obesity
25. Effect of sibutramine on weight maintenance after weight loss: A randomized trial
26. Sibutramine: A novel new agent for obesity treatment
27. Efficacy and safety of sibutramine in obese white and African-American patients with hypertension: A 1-year, double-blind, placebo-controlled, multicenter trial
28. Sibutramine - A review of clinical efficacy
29. Efficacy and tolerability of sibutramine in obese patients: A dose-ranging study
30. Long-term maintenance of weight loss after a very-low-calorie diet: A randomized blinded trial of the efficacy and tolerability of sibutramine
31. Sibutramine produces dose-related weight loss
32. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge
33. Assessing impact of weight on quality of life
34. Beneficial health effects of madest weight loss
35. The case for medical management of obesity: A call for increased physician involvement
36. Defining success in obesity management
37. Regional obesity and risk of cardiovascular disease: The Framingham Study
38. Abdominal adiposity and coronary heart disease in women
39. Current thinking in lipid lawering
40. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study
41. The Helsinki Heart Study: Central findings and clinical implications
42. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol: Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group
43. Drugs for treatment of patients with high cholesterol blood levels and other dyslipidemias
44. Drug treatment of lipid disorders
45. Pharmacologic management of triglycerides